期刊
FRONTIERS IN PHARMACOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.950571
关键词
melanoma; Rsk2; vemurafenib; cyclin D1; FoxO1
资金
- National Natural Science Foundation of China
- [81972480]
This study found that overexpression of RSK2 in melanoma leads to resistance to vemurafenib therapy and is associated with poor overall survival in melanoma patients. In addition, the inhibition of RSK2 can suppress melanoma cell proliferation and enhance sensitivity to vemurafenib.
BRAF inhibitors are commonly used in targeted therapies for melanoma patients harboring BRAF(V600E) mutant. Despite the benefit of vemurafenib therapy, acquired resistance during or after treatment remains a major obstacle in BRAF(V600E) mutant melanoma. Here we found that RSK2 is overexpressed in melanoma cells and the high expression of RSK2 indicates poor overall survival (OS) in melanoma patients. Overexpression of RSK2 leads to vemurafenib resistance, and the deletion of RSK2 inhibits cell proliferation and sensitizes melanoma cells to vemurafenib. Mechanistically, RSK2 enhances the phosphorylation of FOXO1 by interacting with FOXO1 and promoting its subsequent degradation, leading to upregulation of cyclin D1 in melanoma cells. These results not only reveal the presence of a RSK2-FOXO1-cyclin D1 signaling pathway in melanoma, but also provide a potential therapeutic strategy to enhance the efficacy of vemurafenib against cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据